Fulgent Genetics, Inc. filings document operating results, business updates, governance matters, capital-structure activity, and clinical disclosures for a company with laboratory services and therapeutic development operations. Form 8-K reports furnish earnings releases, investor presentation updates, stock repurchase activity, and material-event disclosures tied to the company's business and pipeline.
The company's proxy materials cover board and shareholder voting matters, executive compensation, equity awards, and other governance disclosures. Clinical and regulatory filings include updates related to FID-007 in recurrent or metastatic head and neck squamous cell carcinoma, while broader disclosures address financial performance, risk, and capital allocation.
Fulgent Genetics completed two related transactions to expand its pathology footprint. Its Inform Diagnostics subsidiary closed a Purchase and Sale Agreement to acquire all equity of dermatopathology lab StrataDx for approximately $13.5 million in cash, subject to post-closing adjustments. It also closed an Asset Purchase Agreement to buy substantially all assets and certain liabilities of Bako Diagnostics for approximately $43.4 million in cash. A joint press release cites a combined purchase price of about $56.9 million for the Bako and StrataDx acquisitions. In connection with the asset deal, Fulgent assumed a lease for roughly 29,099 square feet of lab and office space in Alpharetta, Georgia, running through July 31, 2032, with base rent of $15.54 per square foot from August 1, 2025 and 2% annual increases, plus operating expenses. Required acquired-business financial statements and pro forma financial information will be provided by amendment.
Fulgent Genetics, Inc. director and CEO Ming Hsieh, a more than ten percent owner, restructured a prior derivative arrangement tied to company stock. A trust associated with him had entered a prepaid variable forward contract in 2023 covering up to 750,000 shares of common stock.
On March 9, 2026, The Ming Hsieh Trust cancelled this agreement for all 750,000 shares and paid the counterparty an aggregate of $10,708,875. After this payment, those 750,000 shares are no longer pledged to the bank and remain held by entities associated with Hsieh.
Following these actions, Hsieh holds 900,634 common shares directly, and additional common shares indirectly, including 7,895,115 by trust, 220,816 by trust, 1,000 in a Uniform Transfers to Minors Act account, and 1,000 held by an immediate family member.
Fulgent Genetics President and COO Jian Xie reported several tax-related share withholdings of company common stock. On February 26, 2026, 1,140 shares were disposed of at $24.7600 per share to cover tax obligations from vesting restricted stock units. On March 1, 2026, additional tax-withholding dispositions of 1,079 and 8,147 shares occurred at $15.3300 per share. After these transactions, his direct holdings were reported as 375,313 shares of common stock. Separately, 220,816 shares are held indirectly by The Hsieh Family Dynasty Trust, for which Mr. Xie serves on the investment committee and disclaims beneficial interest except for any pecuniary interest.
Fulgent Genetics, Inc. CFO and Treasurer Paul Kim reported several tax-withholding dispositions of common stock tied to previously granted restricted stock units. On February 26 and March 1, 2026, shares were withheld at prices of $24.76 and $15.33 to cover associated tax obligations rather than open-market sales.
Fulgent Genetics Chief Scientific Officer Hanlin Gao reported tax-withholding share dispositions related to restricted stock unit vesting. On February 26, 2026 and March 1, 2026, several small blocks of common stock were withheld at prices of $24.76 and $15.33 per share to cover tax obligations, leaving Gao with direct ownership of just under 1.0 million shares after these administrative transactions.
Fulgent Genetics, Inc. director and CEO Ming Hsieh reported tax-related share dispositions rather than open-market sales. On March 1, 2026, 17,566 common shares at $15.33 per share were withheld to cover tax obligations from vested restricted stock units, leaving him with 900,634 directly held shares.
On February 26, 2026, a prior tax-withholding disposition of 2,949 shares at $24.76 per share left him with 918,200 directly held shares at that time. Indirect holdings as of that date include 7,895,115 shares held by the Dynasty Trust, 220,816 by The Ming Hsieh Trust, and 1,000-share positions in a Uniform Transfers to Minors Act account and an immediate family member’s account.
Fulgent Genetics files its annual report describing a dual business in diagnostic laboratory services and cancer therapeutics. The company combines broad pathology and genetic testing with a nanoencapsulation drug platform, including FID-007 in Phase 2 for head and neck cancer and FID-022 in an early Phase 1/1b trial.
One aggregated customer represented 22% of revenue in both 2025 and 2024, highlighting customer concentration risk. The report outlines extensive U.S. and international regulatory oversight of its labs and drug development, plus evolving rules for lab-developed tests and European IVDR compliance.
The filing notes an aggregate market value of non‑affiliate equity of about $284.3 million as of June 30, 2025, and 31,230,632 common shares outstanding as of February 23, 2026.
Fulgent Genetics reported fourth-quarter 2025 revenue of $83.3 million, up 9% year over year, and a GAAP net loss of $23.4 million or ($0.76) per share. Non-GAAP income for the quarter was $5.2 million, or $0.16 per diluted share.
For full year 2025, revenue reached $322.7 million, growing 14% year over year. The company posted a GAAP net loss of $60.5 million, or ($1.97) per share, but generated full-year non-GAAP income of $13.2 million, or $0.42 per diluted share.
Fulgent ended 2025 with $705.5 million in cash, cash equivalents, restricted cash, and investments in marketable securities, excluding an anticipated tax refund of about $106.3 million. For 2026, it guides to revenue of roughly $350 million, a non-GAAP loss of about ($1.45) per share, and year-end cash and investments of about $685 million, assuming receipt of tax refunds and closing of the Bako and StrataDx acquisition.
Fulgent Genetics CFO Paul Kim reported equity awards and related tax withholdings in company stock. On February 23–24, 2026, he acquired multiple common stock grants tied to time-based and performance-based restricted stock units that vested upon meeting performance milestones from awards granted in 2023, 2024, and 2025.
To satisfy tax withholding obligations triggered by these vestings, shares were withheld at prices around $23 per share rather than sold on the open market. A new restricted stock unit grant will vest over three years, with one-third vesting 12 months after March 1, 2026 and the remainder in quarterly installments, subject to continued service.
Fulgent Genetics, Inc. President and COO Jian Xie reported a mix of stock awards and tax-related share withholdings. On February 24, 2026, he acquired several blocks of common stock at no cost through vested performance-based restricted stock units granted in 2023, 2024, and 2025.
He also received a new grant of 31,962 restricted stock units that vest over three years starting 12 months after March 1, 2026. Shares totaling 3,163, 8,254, 14,751 and 655 were withheld at prices around $23 per share to satisfy tax obligations. Additional indirect holdings are reported in The Hsieh Family Dynasty Trust, where Xie notes only a pecuniary interest.